Nyxoah Sets Sights High After Strong Q4 2025 Earnings
Nyxoah, a leading medical technology company, has made significant strides in its commercialization efforts following FDA approval for its groundbreaking Genio device. In the fourth quarter of 2025, the company achieved impressive milestones, solidifying its position as a key player in the hypoglossal nerve stimulation market.
According to Olivier Taelman, Chief Executive Officer of Nyxoah, the year 2025 was transformative for the company, with several defining milestones achieved. These include the hiring and training of a U.S. commercial team, the development of a strategic launch plan, and the securing of market access for Genio.
The company's hard work paid off on August 8th when it received FDA approval for Genio. This was followed by an aggressive launch plan that saw Nyxoah successfully execute on its focused launch in the United States. The company trained 145 surgeons in 125 high-volume hypoglossal nerve stimulation accounts, with 57 already receiving positive Value Analysis Committee approval.
This resulted in a significant revenue boost for the company, with $4.5 million generated in Q4 alone. This translates to $720,000 in annualized sales rep productivity during the first full quarter of launch. The company's clinical data also demonstrated Genio's clinical efficacy in both supine and non-supine positions, as reflected in its labeling.
Internationally, Nyxoah continued to drive growth in selected markets, including Germany, the United Kingdom, and the Middle East. This was driven by strong Q4 U.S. launch momentum, which resulted in a global gross revenue of EUR 11 million for the year.
Taelman expressed excitement with the first launch results, citing key leading indicators that the company is tracking. These include the training of surgeons, Value Analysis Committee submissions, and reimbursement from Medicare and large commercial payers. The company's sales reps have been busy meeting with multiple surgeons and fleet customers across the U.S., hearing consistent positive feedback on Genio's unique approach.
"Surgeons are attracted by the bilateral stimulation, the single incision procedure, and the consistent therapy efficacy across all sleeping positions," Taelman noted. "This makes Genio unique on the market."
Nyxoah's strong Q4 2025 earnings have set the stage for a promising future for the company. With its commercialization efforts gaining momentum, it will be interesting to see how Nyxoah continues to push the boundaries of medical technology in the years to come.
